0H7R Stock Overview
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Abeona Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.46 |
| 52 Week High | US$8.80 |
| 52 Week Low | US$3.12 |
| Beta | 1.51 |
| 11 Month Change | -2.60% |
| 3 Month Change | 14.20% |
| 1 Year Change | 33.15% |
| 33 Year Change | -61.41% |
| 5 Year Change | n/a |
| Change since IPO | -98.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H7R | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 8.2% | 2.5% | 2.2% |
| 1Y | 33.1% | -15.4% | 9.0% |
Return vs Industry: 0H7R exceeded the UK Biotechs industry which returned -15.4% over the past year.
Return vs Market: 0H7R exceeded the UK Market which returned 9% over the past year.
Price Volatility
| 0H7R volatility | |
|---|---|
| 0H7R Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H7R has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0H7R's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 84 | Vish Seshadri | www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
Abeona Therapeutics Inc. Fundamentals Summary
| 0H7R fundamental statistics | |
|---|---|
| Market cap | US$279.43m |
| Earnings (TTM) | -US$71.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.9x
P/E RatioIs 0H7R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H7R income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$31.40m |
| Gross Profit | -US$31.40m |
| Other Expenses | US$39.63m |
| Earnings | -US$71.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 40.7% |
How did 0H7R perform over the long term?
See historical performance and comparison